Physician profile
Michael S Galitz
NPI 1275503690
$9,514.72
in general payments reported to CMS, 2019-2025
39 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $937 · 2022: $2,320 · 2023: $2,193 · 2024: $2,216 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,257.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,666.90 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,150.89 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $830.21 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $642.56 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $490.85 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $435.66 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.54 | 2021-2025 | Jardiance, Synjardy |
| Beta Bionics, INC. | $402.35 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $387.09 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Amgen INC. | $349.90 | 2022-2025 | Evenity, Tepezza, Prolia |
| Corcept Therapeutics | $347.90 | 2021-2025 | Korlym |
| Abbott Laboratories | $267.28 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Novartis Pharmaceuticals Corporation | $228.42 | 2023-2025 | |
| Abbvie INC. | $213.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.14 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $151.79 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $148.20 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $144.76 | 2023 | Tepezza |
| Insulet Corporation | $139.51 | 2021-2025 | Omnipod |
| Medtronic, INC. | $109.69 | 2022-2023 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $108.26 | 2022-2025 | Imcivree |
| Ibsa Pharma INC. | $94.53 | 2021-2023 | Tirosint, Licart |
| Amryt Pharma Holdings LTD | $84.60 | 2023 | Mycapssa |
| Radius Health, INC. | $74.42 | 2023-2024 | Tymlos |
| Recordati_rare_diseases_inc. | $60.99 | 2022-2025 | Isturisa, Signifor Lar |
| Chiesi USA, INC. | $46.75 | 2024 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $42.58 | 2022-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $41.15 | 2024 | Unithroid |
| Sequel Med Tech, LLC | $38.63 | 2025 | Twiist |
| Kyowa Kirin, INC. | $37.61 | 2023-2024 | Crysvita |
| Mannkind Corporation | $36.05 | 2022-2023 | Afrezza |
| Pfizer INC. | $29.63 | 2022 | |
| Glaxosmithkline, LLC. | $22.75 | 2025 | Arexvy, Shingrix |
| Eusa Pharma (US) LLC | $19.83 | 2022 | |
| Halozyme INC | $19.20 | 2023 | |
| Ascendis Pharma Endocrinology INC | $18.54 | 2025 | Yorvipath |
| Astellas Pharma US INC | $18.34 | 2025 | Veozah |
| Averitas Pharma INC. | $15.28 | 2024 | Qutenza |
| Esperion Therapeutics, INC. | $15.22 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Galitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.